Reimagine regulatory service delivery.
A well-designed molecule-to-market plan starts in discovery and continues into lifecycle management. As you begin to navigate the wide and ever-evolving world of clinical development and drug regulation, you may find your team in need of guidance to help you identify the right indication to prioritize and build around. IQVIA’s Regulatory Affairs and Drug Development Solutions (RADDS) group provides multi-phase support to mitigate common roadblocks. Throughout your drug’s development cycle and beyond, RADDS provides a wide range of services, including: |
![]() |
No two drugs follow identical pathways to the patients who need them. However, RADDS has established tried and true metrics that can help you assemble a path to market that aligns with your goals. RADDS helps customers move through the phases of product development, constructing action plans to answer the following questions (and more):
And the support doesn’t end once marketing authorization is achieved. To ensure continued safety and access for patients, RADDS provides customers with regulatory advice, market application expansion opportunities, and variation documentation.
In a recent webinar hosted by RADDS team members, Michel Denarié, Senior Principal, and Michelle Gyzen, Senior Director, they illuminate how the RADDS team aids customers, breaking down the crucial steps needed at each phase of development. To learn more about the possibilities of partnering with RADDS on your drug’s journey to market, watch the on-demand webinar. To read a full summary and case study about a long-term RADDS partnership that led to cost savings and an expedited timeline, download the comprehensive whitepaper.
Reimagine regulatory service delivery.
Automate and standardize your regulatory management, from correspondence and commitments to registration and tracking.
Meet the challenge of changing stakeholder demands and increasing cost constraints with IQVIA's integrated technology services and analytics-driven offerings.